Next Phase Newsletter

An early-stage seed fund based in Palo Alto, CA focuses on seed stage and sometimes Series A investments. Typical equity allocations range from $500 – 750 K per company. The firm is open to both leading and co-investing. The firm has been investing from a $50M fund and is currently raising a new fund, from which it expects to make new investments. The firm is seeking opportunities from across the US with a focus on the Bay Area.

The firm invests across multiple industries including healthcare IT. The firm prefers products that do not require FDA approval. Within healthcare IT, the firm considers both consumer-facing and enterprise solutions that demonstrate customer traction and large market potential.

The firm can work with incomplete management teams and would require a board seat on a case-by-case basis. The firm has funded companies in which the founders were either current students or recent graduates from top US universities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the Mountain West has approximately $300 million in total assets available for investment. The firm typically makes equity investments in 3 to 4 companies every year, and it has flexibility in terms of capital structures. The average first investment in a company is $2 million- $3 million, though it can invest more or less, depending on the opportunity. The firm prefers to invest in seed and series A (early-stage) companies as an initial investment in a company, though it sometimes makes a first investment in a series B or C round. The firm primarily invests in US-based companies, but it will also consider global companies with a US presence.

The firm is currently looking for investment opportunities in medical devices, biopharma and diagnostics. The firm generally makes investments in product-focused companies in pre-clinical stages with prototypes or other available proof-of-concept work completed. It generally likes to invest in companies that can reach the market with the capital raised from this round of financing. The firm prefers device companies with a 510(k) pathway for regulatory approval, and it will opportunistically consider companies with PMA devices.

The firm seeks to invest in small, early-stage companies with a lean but strong and qualified management / execution team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Chicago-based VC firm is investing from a $250m fund, and is interested in a variety of sectors including the life science field. For life science investments, the firm typically allocates $2-15 million, and prefers to invest in Series B-C rounds. The firm invests in the USA and Canada.

The firm is presently focused on technologies that involve an IT/software component, across the medical devices, diagnostics, and healthcare services sectors in addition to pure digital health opportunities. The firm is open to opportunities in any clinical indication. The firm is only interested in devices and diagnostics that have in-human data.

In the life science sector, the firm is not interested in early-stage opportunities; however the firm is open to both companies with an approved product on the market, and companies with a product in late-stage clinical trials. The firm takes the strength of the management team into consideration.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm that founded in 2000 and is based in the US Midwest has assets under management of over $250 million, and closed a new fund in 2015. The fund typically makes equity investments in U.S.-based companies, with portfolio companies located on both coasts and throughout the central part of the country. The firm will consider investing at all stages, with a focus on seed and early-stage investments, including founding companies. Investment size is up to $12 million throughout a portfolio company’s path to liquidity.

The fund is currently looking for new investment opportunities in the life science space, with a specific focus on biopharmaceuticals and therapeutic medical devices. The firm has previously invested in drugs to treat cancer and cardiac disorders, and in minimally invasive medical devices. The fund does not invest in diagnostics, though may be interested in technology with real-time feedback for procedures.

The fund focuses on identifying and shaping early-stage life science companies in the series A/B rounds to create significant shareholder value. Because of its extensive operating expertise, the fund is able to help entrepreneurs achieve near-term objectives that position their companies for exit.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Europe-based private equity firm founded in 2009 has a fund focused solely on oncology. The firm aims to fill the gap between equity and acquisition, and would be the first to get involved in assets that are seeking to spin-out of universities or research institutes. The firm typically acquires stakes and identifies ways to aggregate oncology technologies. The firm’s investment size ranges from $10M-$25M dependent on the company and product. The firm typically seeks co-investors to participate in a round. The firm has predominantly invested in companies based in the UK, though is open to investments on a global level, and is particularly seeking new opportunities in the US.

The firm invests in all sectors and subsectors of technology in oncology – therapeutics, 510K and PMA medical devices, diagnostics, and healthcare IT, along with oncology technology in palliative care. The firm is particularly loyal to its portfolio companies, as it typically makes investments in early-stage post proof-of-concept companies, and remains in the investment until commercialization.

The firm will help fill the management team, and may actively manage; takeover the management; participate in the advisory board; and/or advise the company after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital founded in 1992 and based in Virginia invests in life science companies primarily in the growth stage or at the series A or B round; if investing early, the firm would be part of a syndicate. The firm typically invests around $1-$15M into early companies, and $10M-$30M into growth stage companies. The firm seeks to make 10-15 new investments within the next year. While the firm focuses on companies based in USA and Canada due to practical matters, they may be open to investments on a global level.

The firm has a primary focus in healthcare IT, particularly in EMR companies, analytics, and any next generation IT tools for enterprise or ambulatory settings. The firm’s secondary focus is in tools and diagnostics, specifically in 510K genomics diagnostics, though is open to any kind of new diagnostic tool or test. The firm currently does not have interest in therapeutics or medical technology. The firm prefers companies with a commercialized product that is producing revenue, though does not have a revenue requirement and may be open to clinical stage products. 

The firm focuses on growth stage companies where 80% of their invested companies have revenue with a product looking to expand in the market and 20% of invested companies at the pre-revenue, close to commercialization stage. The firm typically invests in pre-revenue companies when the technology is close to commercialization (i.e. steps away from approval) and/or when the company has a strong management team with members the firm has known from before.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm located in the US Southeast has $1 billion in assets under management. The firm is interested in companies located all over the globe and makes 1-3 equity investments per year into commercial stage, revenue generating companies. The firm will lead a round if it is less than $20m but – if larger, co-invests alongside other private equity firms that it has relationships with. The minimum investment size is $1 million.

The firm is interested in therapeutics, medical devices, R&D services, and suppliers & engineering. The firm is particularly interested in over-the-counter and consumer health products and is otherwise open to all indication areas. Within medtech, the firm looks for products that have already received regulatory approval. Within therapeutics, the firm will consider Phase 3 or later. Orphan diseases are of interest as well.

The firm has no fixed management team requirements and takes a board seat on all investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com